Allarity Therapeutics, Inc. Operating Expenses
Allarity Therapeutics, Inc. (ALLR) reported Operating Expenses of $2.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- Allarity Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $2.67M, a 35.37% decline year-over-year.
- Allarity Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $2.71M, a 10.64% decline year-over-year.
- Allarity Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $3.24M, a 55.75% decline year-over-year.
- Allarity Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $2.52M, a 79.55% decline year-over-year.
- Allarity Therapeutics, Inc. operating expenses for fiscal 2025 was $12.93M, a 52.55% decline from fiscal 2024.
- Allarity Therapeutics, Inc. operating expenses for fiscal 2024 was $27.24M, a 59.03% increase from fiscal 2023.
- Allarity Therapeutics, Inc. operating expenses for fiscal 2023 was $17.13M, a 50.30% decline from fiscal 2022.
- Allarity Therapeutics, Inc. operating expenses for fiscal 2022 was $34.46M, a 29.77% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.67M 10-Q · filed 2026-08-14 | $5.38M 10-Q · filed 2026-08-14 | $8.62M derived: sum of 3 quarters · filed 2026-08-14 | $11.14M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $2.71M 10-Q · filed 2026-05-15 | $5.95M derived: sum of 2 quarters · filed 2026-05-15 | $8.47M derived: sum of 3 quarters · filed 2026-05-15 | $12.60M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | $3.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.76M derived: sum of 2 quarters · filed 2026-03-30 | $9.89M derived: sum of 3 quarters · filed 2026-08-14 | $12.93M 10-K · filed 2026-03-30 | ||
| 2025-09-30 | $2.52M 10-Q · filed 2025-11-14 | $6.65M derived: sum of 2 quarters · filed 2026-08-14 | $9.69M 10-Q · filed 2025-11-14 | $17.00M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | $4.13M 10-Q · filed 2026-08-14 | $7.17M 10-Q · filed 2026-08-14 | $14.49M derived: sum of 3 quarters · filed 2026-08-14 | $26.80M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $3.04M 10-Q · filed 2026-05-15 | $10.35M derived: sum of 2 quarters · filed 2026-05-15 | $22.67M derived: sum of 3 quarters · filed 2026-05-15 | $26.04M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $7.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $19.63M derived: sum of 2 quarters · filed 2026-03-30 | $23.00M derived: sum of 3 quarters · filed 2026-03-30 | $27.24M 10-K · filed 2026-03-30 | ||
| 2024-09-30 | $12.31M 10-Q · filed 2025-11-14 | $15.68M derived: sum of 2 quarters · filed 2025-11-14 | $19.92M 10-Q · filed 2025-11-14 | $24.80M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $3.37M 10-Q · filed 2025-08-15 | $7.61M 10-Q · filed 2025-08-15 | $12.49M derived: sum of 3 quarters · filed 2025-08-15 | $16.92M derived: sum of 4 quarters · filed 2025-08-15 | ||
| 2024-03-31 | $4.24M 10-Q · filed 2025-05-09 | $9.12M derived: sum of 2 quarters · filed 2025-05-09 | $13.54M derived: sum of 3 quarters · filed 2025-05-09 | $17.70M derived: sum of 4 quarters · filed 2025-05-09 | ||
| 2023-12-31 | $4.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $9.30M derived: sum of 2 quarters · filed 2025-03-31 | $13.46M derived: sum of 3 quarters · filed 2025-03-31 | $17.13M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $4.43M 10-Q · filed 2024-11-14 | $8.58M derived: sum of 2 quarters · filed 2024-11-14 | $12.25M 10-Q · filed 2024-11-14 | $19.00M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $4.16M 10-Q · filed 2024-08-05 | $7.82M 10-Q · filed 2024-08-05 | $14.57M derived: sum of 3 quarters · filed 2024-08-05 | $19.14M derived: sum of 4 quarters · filed 2024-08-05 | ||
| 2023-03-31 | $3.67M 10-Q · filed 2024-05-14 | $3.66M 10-Q · filed 2023-05-11 | $10.42M derived: sum of 2 quarters · filed 2024-05-14 | $14.98M derived: sum of 3 quarters · filed 2024-05-14 | $19.82M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | $6.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $11.31M derived: sum of 2 quarters · filed 2024-03-08 | $16.15M derived: sum of 3 quarters · filed 2024-03-08 | $34.46M 10-K · filed 2024-03-08 | ||
| 2022-09-30 | $4.56M 10-Q · filed 2023-11-14 | $9.40M derived: sum of 2 quarters · filed 2023-11-14 | $27.71M 10-Q · filed 2023-11-14 | $43.45M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $4.84M 10-Q · filed 2023-08-14 | $23.15M 10-Q · filed 2023-08-14 | $38.89M derived: sum of 3 quarters · filed 2023-08-14 | $42.87M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $18.31M 10-Q · filed 2023-05-11 | $34.05M derived: sum of 2 quarters · filed 2023-05-11 | $38.02M derived: sum of 3 quarters · filed 2023-05-11 | $42.40M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $15.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $19.72M derived: sum of 2 quarters · filed 2023-03-13 | $24.09M derived: sum of 3 quarters · filed 2023-03-13 | $26.56M 10-K · filed 2023-03-13 | ||
| 2021-09-30 | $3.97M 10-Q · filed 2022-11-14 | $3.19M 10-Q · filed 2021-11-23 | $8.35M derived: sum of 2 quarters · filed 2022-11-14 | $10.81M 10-Q · filed 2022-11-14 | $10.47M 10-Q · filed 2021-11-23 | $13.33M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $4.38M 10-Q · filed 2022-10-07 | $6.84M 10-Q · filed 2022-10-07 | $9.36M derived: sum of 3 quarters · filed 2022-10-07 | $11.10M derived: sum of 4 quarters · filed 2022-10-07 | ||
| 2021-03-31 | $2.46M 10-Q · filed 2022-05-27 | $4.98M derived: sum of 2 quarters · filed 2022-05-27 | $6.72M derived: sum of 3 quarters · filed 2022-05-27 | |||
| 2020-12-31 | $2.52M derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-05-17 | $4.26M derived: sum of 2 quarters · filed 2022-05-17 | $8.32M 10-K · filed 2022-05-17 | |||
| 2020-09-30 | $1.74M 10-Q/A · filed 2022-05-17 | $1.97M 10-Q · filed 2021-11-23 | $5.80M 10-Q/A · filed 2022-05-17 | $6.48M 10-Q · filed 2021-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |